Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=13053 Anyone following Barr Labs BRL? Today it closed at 35 7/8 up 3 on no news. Any good rumors cooking out there? They are waiting for an FDA approval for their conjugated estrogen product (market estimated at $1 billion) This is all I could find from my files. Post if you run into something more recent! How long can AHP American Home hold back the approval process of Conjugated estrogens: Medicine: Premarin Maker Ties Up FDA To Fight Rivals The Wall Street Journal--January 24, 1997 EXCERT from Motley Fool Nightly News of January 29, 1997 BARR LABORATORIES (AMEX: BRL) gained $1 5/8 to 34 1/4 after the generic drug company announced the availability of its 50 milligram-strength Demerol equivalent. The drug is a common painkiller for moderate to severe pain and is prescribed around the world. Any news of this type is a positive for Barr, since the company relied upon the distribution of a breast-cancer treatment, Tamoxifen Citrate, for 75% of its sales last quarter. Despite the danger inherent in relying upon low-margin distribution sales, investors have bid up Barr from its summer low of $22 3/8. Now trading at 58 times annualized earnings, the idea is that Barr can get its operating margin somewhere north of 15%. On yearly sales of $250 million+, that would bring the P/E down to the 20s range, in-line with the rest of the industry. My comments: It seems that your coverage on Barr is quite biased, anemic and laced with amnesia. The PE of 56 is based on FUNDAMENTALS!!!! Barr has consistently reported NEWS which will have a positive impact on SALES and Earnings. The news today is part of Barr's strategy to differentiate itself from all other generics. It is evident that in thecourts they have been quite sucessfull with the Tamoxifen and CIPRO decision which will be positive $$$$ for their earnings. A cool $24.55 million to be paid in January 1997 and (quote from BRL, but check out the official press release: "The settlement of the patent challenge is comprised of two components:an initial cash payment to Barr of $24.55 million, paid in January 1997, and a contingent, non-exclusive Supply Agreement which becomes effective in January 1998 and endswith the expiration of the patent in December 2003. Under the contingent Supply Agreement, Bayer has the option to make payments to Barr or to provide Barr with quantitiesof ciprofloxacin that Barr would market pursuant to a license from Bayer. Barr believes thatthe annual value of the settlement to Barr has the potential to provide value similar to that received in 1997". The press release says a cash payment of $24.55 million. Am I missing something???? How about that for a company with 1996 net income of $7 Million. Thatadds up to $2.16 EPS, with a stock price of $34 that gives a PE of 15.7!!!!!!!!!!!!!! To bring your analysis in perspective the expected share price should be $43.2. Not bad. The stocks are going up based on all the following...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=1305338013210